FPI stands for First Patient In, a milestone in clinical trials that marks the moment the very first participant is enrolled and begins the study. You may also see it written as FPFV (First Patient First Visit), which means the same thing. FPI is one of the most closely watched dates in any trial because it signals the transition from planning and preparation into active research with real participants.
Where FPI Falls in the Trial Timeline
Clinical trials follow a predictable sequence of milestones, and FPI sits right at the boundary between setup and enrollment. The standard progression looks like this:
- Protocol approval: the study design is finalized and approved
- FPI (First Patient In): the first participant is enrolled and has their first visit
- LPI or LPFV (Last Patient First Visit): the final participant is enrolled, closing the recruitment window
- LPLV (Last Patient Last Visit): the final participant completes their last study visit
- Database lock: the data is cleaned, finalized, and locked for analysis
Each gap between these milestones has a name. The period from protocol approval to FPI is called study initiation. The period from FPI to LPI is enrollment duration. The period from LPI to LPLV is treatment duration. These segments help sponsors, regulators, and research teams measure how efficiently a trial is running and where bottlenecks are forming.
Why FPI Matters So Much
FPI is more than a date on a calendar. It serves as a proof point that all the behind-the-scenes preparation actually worked: regulatory bodies approved the study, ethics committees signed off, contracts were executed, supplies were delivered, and at least one site was ready to see patients. Until FPI happens, a trial is still theoretical. After FPI, it’s real.
For pharmaceutical companies and their investors, FPI is a signal that a drug development program is on track. Delays to FPI can push back the entire development timeline, potentially costing millions per day for large programs. Contract research organizations (the companies hired to run trials) often tie their payment schedules to milestones like FPI, meaning it triggers real financial consequences for everyone involved.
How Long It Takes to Reach FPI
The time between regulatory approval and FPI varies enormously depending on the country, the complexity of the trial, and how smoothly the startup process goes. A large multinational trial published in JAMA Network Open found that the median time from regulatory and ethical approval to FPI was 89 days across 16 countries, but the range stretched from as few as 5 days to over 1,000.
Geography played a major role. In the UK, the median was just 26 days. In non-UK countries, it ballooned to 116 days, roughly three months longer. That gap reflects differences in regulatory systems, contracting processes, and how quickly individual hospital sites can get up and running.
What Has to Happen Before FPI
Reaching FPI requires clearing a long checklist of regulatory, logistical, and administrative hurdles. At a minimum, teams need a finalized study protocol, a data and safety monitoring plan, approved informed consent documents, and completed case report forms. The study database has to be built and validated. If the trial involves an independent oversight board, that review needs to be complete as well.
At the individual site level, sponsors or their contracted research organizations require a signed contract, an approved budget, ethics committee approval, investigator credentials, financial disclosure forms, and various regulatory documents before a site can open to enrollment. A single error on a critical document, like an informed consent form or insurance certificate, can prevent a site from enrolling anyone until it’s corrected.
Common Reasons FPI Gets Delayed
Delays to FPI are one of the most persistent problems in clinical research. A systematic review of startup delays in global randomized trials identified several recurring culprits.
Regulatory approvals top the list. Different countries have different submission requirements, and navigating them simultaneously for a multinational trial is slow work. Some countries require local ethics committees that meet infrequently, creating waiting periods that can stretch for weeks. Additional requirements that surface after the initial approval add further delays.
Contract and budget negotiations between sponsors and individual hospital sites are another major source of friction. These negotiations can drag on for months, particularly when legal teams on both sides are working through liability terms, payment schedules, and intellectual property provisions.
Insurance procurement is an often-underestimated bottleneck. Proof of liability insurance is required as part of the regulatory submission in some countries, and securing appropriate coverage for a multinational trial adds both cost and time to the startup process.
Clinical supply logistics create their own challenges. Every participating country has specific language and regulatory requirements for study drugs, devices, and materials. Getting supplies manufactured, labeled, shipped, and cleared through customs to remote sites around the world takes careful coordination, and any misstep can hold up enrollment at that location.
FPI vs. Related Terms
You’ll encounter several variations of this milestone depending on who’s writing about it. FPI (First Patient In), FPFV (First Patient First Visit), and FSI (First Subject In) all refer to the same event. Some organizations prefer “subject” over “patient,” and some specify “first visit” to be more precise, but the meaning is identical: the first person has entered the study.
FPI should not be confused with FPD (First Patient Dosed), which applies specifically to drug trials and marks the moment the first participant actually receives the study treatment. In many trials FPI and FPD happen on the same day, but in studies with screening periods or run-in phases, there can be a gap of days or weeks between enrollment and dosing.